|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings GP/FP/Primary care






Infectious disease 





Paediatrics 





Key Words: chloramphenical conjunctivitis (bacterial) conjunctivitis (viral)
| The first 150 words of the full text of this article appear below. |
METHODS
Design:
randomised controlled trial.
Allocation:
concealed.*
Blinding:
blinded (patients, healthcare providers, data collectors, outcome assessors, and data analysts).*
Follow up period:
7 days for the primary outcome plus an extra 5 weeks to assess relapse.
Setting:
12 primary care practices in Oxfordshire, UK.
Patients:
326 children 6 months to 12 years of age who had acute infective conjunctivitis. Exclusion criteria included an allergy to chloramphenicol, use of an antibiotic (current or within the previous 48 h), evidence of severe infection, and children who were immunocompromised.
Intervention:
0.5% chloramphenicol (preservative free eye drops BP) (n = 163) or placebo (distilled water with the excipients boric acid, 1.5%, and borax, 0.3%) (n = 163). Parents were instructed to put 1 drop in each of their childs affected eye every 2 hours for the first 24 hours when their child was awake and then 4 times daily until 48 hours after the infection
Morten Lindbaek, MD
University of Oslo
Oslo, Norway
Relevant Article
Evid. Based Med. 2006 11: 31.
(in Glossary)
This article has been cited by other articles:
![]() |
K. M Qureshi, S. Robbie, S. Kashani, and P. Rose Viral infections need to be excluded from the cohort for the results to be truly meaningful * Author's reply Evid. Based Med., June 1, 2007; 12(3): 93 - 93. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |